Indian Pharma Aims To Double In Size By 2030, Says Torrent's Samir Mehta

The Indian pharmaceutical industry aims to more than double its size to $120-130 billion by 2030, driven by innovation and a vision to become the global healthcare leader, said Samir Mehta, president of the Indian Pharmaceutical Alliance and chairman of Torrent Group.

Over the past 25 years, the industry has grown nearly 20 times, reaching a market size of $58 billion from $3 billion in 1999-2000, with domestic sales and exports now contributing equally. The pharmaceutical sector is also one of the top five contributors to India’s trade surplus, which has increased from $1 billion to $19.5 billion in the same period.

In an article on the occasion of IPA’s 25th anniversary, Mehta highlighted that the industry's growth is a result of key policy reforms combined with entrepreneurial spirit. As India moves towards its 2047 goals, he emphasised that the pharmaceutical sector will be central to driving job creation, global trade, innovation, and public health.

Mehta also stressed the importance of a supportive policy framework, strong R&D investment, and affordable healthcare access to unlock the sector’s full potential, with collaboration among industry stakeholders, regulators, and academic institutions playing a key role in achieving these aspirations.

"Embracing the ancient Indian philosophy of 'Vasudhaiva Kutumbakam,' meaning the world is one family, India is poised to be the healthcare custodian of the world," he said.

India's excellence in producing high-quality, affordable generic drugs and vaccines has positioned the nation as a key player on the global stage, he said. On the global stage, India carries weight to advocate for crucial issues such as trade, sustainability, innovation, technology and healthcare.

"India's role in the new global order has never been more apparent than during the recent battle against the COVID-19 pandemic. The nation rose to the occasion to ensure a consistent supply of life-saving medicines to patients globally, cementing its leadership position in global healthcare," he said.

This achievement is not accidental but a result of years of dedication to innovation, excellence in manufacturing, and consistently meeting global quality standards.

"Our perseverance has been tested over time, and we have consistently demonstrated our resilience in the face of adversity. Today's success is built on the hard work of the past, and the decisions we make now will pave the way for a prosperous future," he said.

The Indian pharmaceutical industry is a crucial component of the country's growth narrative.

Mehta said as a global manufacturing powerhouse, India supplies 20% of the world's generic drug demand and ranks 11th in terms of volume and value.

"Today, the global healthcare landscape is undergoing a significant paradigm shift - a shift in disease patterns and population age, consumerisation of healthcare and increasing focus on holistic health," he said. "Indian pharma aims to grow to $120-130 billion by 2030 and $400-450 billion by 2047."

Capturing this opportunity in the coming decades would require four key enablers - the focus needs to be on robust funding mechanisms and building talent adept at life sciences (biopharma) and digital technologies to foster innovation.

Also, to aspire and maintain global leadership in pharma, there is a need to enable and follow globally benchmarked regulations. There is also a need to efficiently integrate technologies for drug discovery, manufacturing and commercialisation at scale and convergence of drugs, data and devices.

Lastly, augmenting existing infrastructure to achieve self-reliance across the supply chain will be critical for healthcare security, he said. 'The Bulk Drug Parks, Production Incentive Schemes aimed at self-reliance and making global champions from India will help create world-class manufacturing and R&D hubs.

(With Inputs From PTI)